RASSF1A: A promising target for the diagnosis and treatment of cancer

Clin Chim Acta. 2020 May:504:98-108. doi: 10.1016/j.cca.2020.01.014. Epub 2020 Jan 23.

Abstract

The Ras association domain family 1 isoform A (RASSF1A), a tumor suppressor, regulates several tumor-related signaling pathways and interferes with diverse cellular processes. RASSF1A is frequently demonstrated to be inactivated by hypermethylation in numerous types of solid cancers. It is also associated with lymph node metastasis, vascular invasion, and chemo-resistance. Therefore, reactivation of RASSF1A may be a viable strategy to block tumor progress and reverse drug resistance. In this review, we have summarized the clinical value of RASSF1A for screening, staging, and therapeutic management of human malignancies. We also highlighted the potential mechanism of RASSF1A in chemo-resistance, which may help identify novel drugs in the future.

Keywords: Cancer; DNA methylation; Diagnosis; Drug resistance; RASSF1A; Therapy.

Publication types

  • Review

MeSH terms

  • DNA Methylation*
  • Humans
  • Lymphatic Metastasis
  • Promoter Regions, Genetic
  • Tumor Suppressor Proteins* / genetics
  • Tumor Suppressor Proteins* / metabolism

Substances

  • Tumor Suppressor Proteins